Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$GYRE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 • Reported revenue of $29.11M up 8.72% YoY • Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.

Price since post

Full Details

Advertisement|Remove ads.